The proposed changes by the Centers for Medicare and Medicaid Services (CMS) regarding payment for diabetes technology have garnered attention from medtech companies like Insulet and Tandem Diabetes Care. The proposed rule aims to include insulin pumps and continuous glucose monitors in a competitive bidding program while shifting payments to a monthly rental schedule. This move could potentially lead to a more competitive environment, especially affecting companies like Tandem and Medtronic, according to analysts.
While some companies anticipate minimal impacts, Tandem Diabetes Care’s CFO, Leigh Vosseller, expressed confidence that the changes won’t significantly affect their business and might even drive more people towards pump therapy. Tandem, which currently operates under a durable medical equipment model, is looking to transition to a pay-as-you-go model, aligning with their plans to sell supplies for their t:slim X2 pump through pharmacies. The company is actively participating in the comment period and is awaiting final rulings by November.
On the other hand, Insulet seems less concerned about the CMS changes as their devices are already sold on a pay-as-you-go basis mainly through the pharmacy channel. Insulet’s CEO, Ashley McEvoy, emphasized that their Omnipod 5 technology offers unique benefits for diabetes care and doesn’t foresee their products falling under competitive bidding. The company has even raised its sales growth expectations for 2025, reflecting confidence in their market position.
Dexcom, a key player in continuous glucose monitoring, also weighed in on the CMS bidding proposal, highlighting that a portion of their business comes from fee-for-service Medicare. The company plans to ensure uninterrupted care for Medicare beneficiaries and remains cautious about potential disruptions in the bidding process. With significant market shares in diabetes technology, these companies are closely monitoring the regulatory landscape to navigate potential impacts and opportunities.
Despite challenges such as a recent recall related to a speaker problem affecting Tandem’s devices, the company remains resilient and is adapting its strategies to align with evolving market dynamics. As the medtech sector continues to evolve, companies are focused on innovation, market access, and regulatory compliance to sustain growth and address the needs of patients with diabetes effectively.
Key Takeaways:
– Changes in CMS payment rules for diabetes technology could introduce a more competitive landscape.
– Companies like Tandem and Insulet are adapting their business models to align with potential payment shifts.
– Continuous glucose monitoring companies like Dexcom are monitoring the situation closely to ensure uninterrupted care for Medicare beneficiaries.
– Despite challenges, medtech companies are optimistic about growth opportunities and remain committed to improving diabetes care.
Read more on finance.yahoo.com